-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 31, Hanhui Pharmaceuticals announced major organizational structure adjustments and personnel appointments.
According to Dami’s understanding, today Hanhui Pharmaceutical also announced a number of personnel changes in important positions, including Yu Tieming’s resignation as the company’s chief financial officer, Li Hao’s succession, and the appointment of He Dong as the vice president of the National Commercial and Diversified Business Department.
In terms of organizational structure, Hanhui Pharmaceutical will no longer establish a national sales business department and COO positions.
In addition, Liu Qi was appointed as the chairman of Hanhui Pharmaceutical and the general manager of the preparations section of Hisun Pharmaceutical.
Li Yan took up the position of CEO of Hanhui Pharmaceutical since 2017.
On February 28, 2017, Hisun Pfizer, the predecessor of Hanhui Pharmaceuticals, announced that Mr.
Da Mi had previously introduced to his friends that Li Yan graduated from Fudan University with a major in economics and obtained an MBA degree from the Simon Business School of the University of Rochester in the United States.
In addition to the CEO position of Hanhui Pharmaceuticals, Li Yan is also the director and president of Hisun Pharmaceuticals, the parent company of Hanhui Pharmaceuticals.
